SPHK1 and hematocrit: Recent studies have demonstrated substantial dysregulation of SPL metabolism in both patients with HT and experimental autoimmune thyroiditis models, with a particular emphasis on the aberrant activation of the SPHK/S1P/S1PR signaling axis [18].